J&J secures expanded FDA approval for Tremfya to include ulcerative colitis
Tremfya is a dual-acting interleukin-23 inhibitor approved in active ulcerative colitis (UC) and showed highly statistically significant rates of endoscopic remission at one year in the Phase 2b/3 Quasar clinical...
Effects of interstate armed conflicts on the pharmaceutical industry
Unveiling the impact of misinformation and disinformation in the pharmaceutical industry
The ripple effects of inflation on the pharmaceutical industry
Extreme weather events: The implications for the pharmaceutical industry